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ABSTRACT	
Purpose:	 Endocrine	 therapy	 is	 the	 standard	 treatment	 for	 estrogen	 receptor-posi\ve	 (ER+)	 breast	
cancer.	 Despite	 its	 efficacy,	 around	 half	 of	 pa\ents	 will	 develop	 resistance	 to	 this	 treatment	 and	
eventually	 relapse.	 Iden\fica\on	of	 effec\ve	and	 reliable	biomarkers	 to	predict	 the	efficacy	of	 en-
docrine	therapy	is	of	crucial	importance	in	the	management	of	ER+	breast	cancer.	Emerging	evidence	
has	revealed	that	the	cell	division	regulator	CDC20	exhibits	an	oncogenic	func\on	and	plays	impor-
tant	 roles	 in	 tumourigenesis	 and	 progression	 of	 solid	 tumours.	 In	 this	 study,	 we	 inves\gated	 the	
prognos\c	and	predic\ve	role	of	CDC20	in	early	ER + breast	cancer	pa\ents.	
Methods:	The	biological	and	clinical	impact	of	CDC20	expression	was	assessed	in	large	clinical	annot-
ated	cohort	of	ER+	breast	cancer	with	long-term	follow-up	at	the	mRNA	level,	using	METABRIC	and	
KM-Plocer	 datasets,	 and	 the	 protein	 level	 using	 immunohistochemistry	 on	 pa\ents	 presen\ng	 at	
NoHngham.	CDC20	expression	was	correlated	with	clinico-pathological	parameters,	molecular	sub-
types,	clinical	outcome	and	efficacy	of	endocrine	therapy.	
Results:	High	CDC20	mRNA	expression	was	associated	with	poor	clinico-pathological	parameters	in-
cluding	large	tumour	size	and	high	tumour	grade	(P<0.0001)	in	pa\ents	with	ER+	breast	cancer.	High	
CDC20	mRNA	expression	was	significantly	associated	with	poor	pa\ent	outcome	(P<0.0001).	Import-
antly,	high	CDC20	expression	was	correlated	with	poor	response	to	endocrine	treatment	in	pa\ents	
who	treated	with	hormonal	therapy	only	(P<0.01).	In	mul\variate	analysis,	CDC20	mRNA	was	an	in-
dependent	predictor	of	poor	clinical	outcome	aeer	treatment	with	endocrine	therapy	(P=	0.02).	
Conclusion:	CDC20	 is	a	 candidate	biomarker	 for	a	 subgroup	of	ER+	breast	 cancer	 characterised	by	
poor	clinical	outcome.	This	study	shows	that	the	CDC20	could	act	as	poten\al	predic\ve	biomarker	
of	poor	response	to	endocrine	therapy	in	ER+	breast	cancer.	
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INTRODUCTION	
Breast	cancer	is	a	heterogeneous	disease	with	various	biological	subtypes	[1]	with	the	most	common	
form,	approximately	75%,	 	of	breast	cancer	being	oestrogen	receptor	posi\ve	(ER+)	[2,3].	Endocrine	
therapy	is	the	main	treatment	for	ER+	tumours,	which	has	vastly	improved	survival	and	has	reduced	
mortality	 [4].	However,	a	high	propor\on	of	pa\ents	 receiving	adjuvant	endocrine	 therapy	s\ll	ex-
perience	relapse	and	become	resistant	to	treatment	[5,6].	It	is	therefore	highly	desirable	to	predict,	
at	an	early	stage	of	treatment,	which	ER+	pa\ents	will	and	will	not	benefit	from	endocrine	therapy.	
Cell	division	cycle	20	homolog	(CDC20)	is	a	spindle	assembly	checkpoint	molecule	that	required	for	
the	anaphase-promo\ng	complex/cyclosome	(APC/C)	ac\va\on	during	mitosis,	 leading	to	 ini\a\on	
of	 chroma\d	 separa\on	and	entrance	of	 cell	 cycle	 into	anaphase	 [7,8].	Defects	 in	CDC20	 func\on	
may	therefore	terminate	mito\c	arrest,	which	lead	to	tumourgenesis	[9,10].	Consistent	with	the	no-
\on	that	CDC20	may	func\on	as	an	oncogene,	several	studies	show	overexpression	of	CDC20	in	dif-
ferent	types	of	cancers	[11,12,9,13].	Indeed,	its	overexpression	is	suggested	as	a	biomarker	of	poor	
outcome	in	pancrea\c	[14],	colon	[15],	primary	non-small	cell	lung	[16]	and	ovarian	cancer	[11].	
In	terms	of	breast	cancer,	two	reports	have	demonstrated	that	CDC20	is	a	poten\al	key	player	in	the	
progression	 of	 breast	 cancer	 where	 it	 is	 significantly	 higher	 in	 breast	 cancer	 cells	 and	 high-grade	
primary	tumour	\ssues	[17]	and	indicates	an	aggressive	course	of	disease	risk	[18].	We	aimed	to	in-
ves\gate	 the	 role	of	CDC20	expression	 in	ER+	 tumours.	 In	par\cular,	we	assessed	whether	CDC20	
had	a	role	in	endocrine	resistance	which	could	be	used	to	improve	therapy	predic\on	in	ER+	breast	
cancer.	
MATERIALS	AND	METHOD	
CDC20	mRNA	expression	
The	Molecular	 Taxonomy	 of	 Breast	 Cancer	 Interna\onal	 Consor\um	 (METABRIC)	 [19],	 comprising	
1,506	ER+	breast	cancer,	was	used	as	a	discovery	cohort	to	analyse	and	explore	the	prognos\c	value	
of	 CDC20	mRNA	and	 its	 role	 as	 predic\ve	biomarker	 of	 clinical	 outcome	 for	 pa\ents	who	 treated	
with	endocrine	therapy,	Table	1.	
The	Kaplan	Meier	 Plocer-Breast	 Cancer	 (KM-Plocer)	 online	 dataset	 [20],	was	 used	 as	 a	 valida\on	
cohort	for	the	prognos\c	and	predic\ve	value	of	CDC20	mRNA	expression	using	2,061	pa\ents	with	
ER+	breast	cancer.	The	prognos\c	value	of	CDC20	mRNA	expression	and	associa\on	with	clinical	out-
come	and	clinico-pathological	parameters	were	further	validated	using	the	Breast	Cancer	Gene-Ex-
pression	Miner	v4.0	 (bc-GenExMiner	v4.0)	database	 [21]	which	 includes	5,829	cases	of	ER+	breast	
cancer.	
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CDC20	protein	expression	
CDC20	protein	expression	was	assessed	 in	a	series	cohort	of	clinical	 samples	 for	pa\ents	with	ER+	
(n=	347)	using	immunohistochemistry	(IHC).	Pa\ents	presented	at	NoHngham	City	Hospital	between	
1989	and	2006.	Pa\ent	management	was	uniform	and	based	on	tumour	characteris\cs	by	NoHng-
ham	Prognos\c	Index	(NPI)	and	hormone	receptor	status.	No	adjuvant	therapy	was	given	to	pa\ents	
with	good	prognos\c	NPI	score	(≤3.4),	while	for	pa\ents	with	poor	NPI	scores	(>3.4)	endocrine	ther-
apy	was	 given.	 Premenopausal	 pa\ents	within	 the	moderate	 and	 poor	 prognos\c	NPI	were	 given	
chemotherapy,	 whereas	 postmenopausal	 pa\ents	 with	moderate	 or	 poor	 NPI	 were	 candidate	 for	
hormonal	therapy.	None	of	the	pa\ents	in	this	study	received	neoadjuvant	therapy.	Clinical	history,	
informa\on	on	therapy	and	outcomes	and	tumour	characteris\cs	are	prospec\vely	maintained.	The	
clinico-pathological	parameters	for	the	cohort	series	are	summarised	in	Table	1.	
Western	bloPng	
ImmunobloHng	was	performed	as	previously	described	[22],	the	specificity	of	CDC20	was	validated	
on	BT474	human	breast	 cancer	 cells	 (American	Type	Culture	Collec\on;	Rockville,	MD,	USA)	using	
primary	CDC20	an\body	(HPA039484,	Sigma-Aldrich,	1:2000).	This	showed	a	specific	band	for	CDC20	
protein	at	the	predicted	size	of	55	kDa	(Fig.	1A).	
IHC	staining	and	Evalua4on	
Tumour	samples	were	arrayed	as	previously	described	[23].	The	IHC	staining	was	performed	on	4	μm	
\ssue	 microarrays	 (TMAs)	 sec\ons	 using	 Novolink	 polymer	 detec\on	 system	 (Leica	 Biosystems,	
RE7150-K),	 detailed	method	was	 described	 in	 previous	 publica\on	 [22].	 Sec\ons	were	 incubated,	
overnight	at	4	°C,	with	the	primary	CDC20	an\body	diluted	at	1:500.	CDC20	immunoreac\vity	was	
assessed	 using	 high-resolu\on	 digital	 images	 (Nanozoomer,	 Hamamatsu	 Photonics)	 and	 viewing	
soeware	(Xplore;	Philips,	UK).	Evalua\on	was	based	on	a	semiquan\ta\ve	assessment	using	a	modi-
fied	histochemical	score	(H-score),	which	includes	an	assessment	of	both	the	intensity	and	the	per-
centage	of	stained	cells	[24].	The	staining	intensity	of	invasive	tumour	cells	was	scored	into	four	cat-
egories	0	(no	staining);	1	(weak	staining);	2	(moderate	staining)	and	3	(strong	staining).	The	percent-
age	of	each	category	was	es\mated,	and	 the	H-score	 calculated.	TMA	cores	were	only	assessed	 if	
tumour	burden	was	>15%.		
Clinical	outcome	data	and	events	defini4on	
Clinical	outcomes	including	breast	cancer	specific	survival	(BCSS)	was	defined	as	the	\me	in	months	
from	the	diagnosis	to	the	date	of	breast	cancer-related	death.	Recurrence	free	survival	(RFS)	was	de-
fined	 as	 the	 \me	 in	months	 from	diagnosis	 un\l	 developing	 local	 or	 regional	 recurrence.	 Distant-
metastasis	free	survival	(DMFS)	was	defined	as	the	\me	in	months	from	diagnosis	un\l	developing	
distant-metastasis.	For	 the	benefit	of	endocrine	therapy,	 the	expression	of	CDC20	was	 inves\gated	
with	clinical	outcome	on	the	endocrine	treated	cohort	only.	Secondary	outcomes	 included	associa-
\ons	with	clinico-pathological	parameters.	
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Sta4s4cal	analysis	
Data	analysis	was	performed	using	SPSS	sta\s\cal	soeware	(version	25,	Chicago,	IL,	USA).	The	analy-
sis	for	this	study	compared	low	and	high	expression	of	CDC20.	The	Chi-square	test	was	performed	for	
inter-rela\onships	between	categorical	variables.	Spearman’s	correla\on	coefficient	was	used	to	ex-
amine	the	associa\on	between	con\nuous	variables.	One-way	analysis	of	variance	(ANOVA)	with	the	
post-hoc	Tukey	was	used	for	differences	between	three	or	more	groups.	Kaplan-Meier	analysis	was	
used	to	assess	the	associa\on	of	CDC20	expression	with	clinical	outcome.	Mul\variate	Cox	Regres-
sion	analysis	with	adjustment	of	covariates	was	used	to	iden\fy	independent	prognos\c	biomarkers.	
Benjamini–Hochberg	procedure	 for	mul\ple	 test	 correc\on	was	performed.	 P	 value	of	 ≤	 0.05	was	
considered	 significant.	 The	 dichotomisa\on	 of	 CDC20	mRNA	 and	 protein	 expression	 into	 low	 and	
high	 groups	 was	 determined	 using	 X-Tile	 (X-Tile	 Bioinforma\cs	 Soeware,	 Yale	 University,	 version	
3.6.1).	
RESULTS	
CDC20	expression	in	ER+	BC	
High	CDC20	mRNA	expression	in	the	METABRIC	cohort	was	observed	in	870	cases	(58%),	where	low	
expression	was	observed	 in	 636	 cases	 (42%).	 CDC20	protein	 expression	was	 localised	 to	 the	 cyto-
plasm	of	 invasive	 tumour	 cells,	with	 expression	 levels	 varying	 from	 absent	 to	 high	 (H-score	 range	
0-250)	(Fig.	1B	and	1C).	CDC20	expression	was	dichotomised	into	low	and	high	using	an	H-score	of	
120	resul\ng	in	85	(25%)	cases	showing	high	expression	and	262	(75%)	cases	with	low	expression.	
Associa4on	of	CDC20	expression	with	clinic-pathological	characteris4cs	in	ER+	breast	cancer	
CDC20	mRNA	 expression	was	 associated	with	 aggressive	 clinico-pathological	 parameters	 including	
nega\ve	 expression	 of	 PR,	 poor	 NoHngham	 Prognos\c	 Index	 (NPI)	 and	 high	 tumour	 grade	
(P<0.0001,	Fig.	2A-2C)	using	the	METABRIC	dataset.	The	associa\on	with	PR	and	NPI	was	validated	
using	the	bc-GenExMiner	v4.0	dataset	(P<	0.0001;	Supplementary	Fig.	1A	and	1B).	In	contrast,	CDC20	
protein	expression	showed	no	sta\s\cal	significance	associa\on	with	any	of	the	clinico-pathological	
parameters.	
The	METABRIC	dataset	was	used	to	inves\gate	the	correla\on	between	CDC20	mRNA	and	prolifera-
\on	 related-genes.	 There	was	 posi\ve	 correla\on	 of	 CDC20	mRNA	with	 the	 expression	 of	MKI67,	
CCNB1,	CCNA2	and	CCND1	(p<	0.0001),	Table	2.	These	findings	were	validated	using	bc-GenExMiner	
v4.0	dataset	(P<	0.0001;	Fig.	2D-2G).	
Clinical	significance	of	CDC20	in	pa4ents	with	ER+	BC	
High	mRNA	CDC20	expression	was	significantly	correlated	with	poor	clinical	outcome.	Thus,	results	
of	METABRIC	dataset	showed	that	high	expression	of	CDC20	mRNA	was	associated	with	poor	RFS	(P<	
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0.0001),	DMFS	(P<	0.0001)	and	high	risk	of	death	from	breast	cancer	(P<	0.0001)	(Fig.	3A-3C).	To	fur-
ther	validate	our	findings	we	used	the	KM-Plocer	dataset	which	showed	that	high	mRNA	expression	
of	 CDC20	 was	 also	 associated	 with	 poor	 clinical	 outcomes	 including	 RFS	 (P<	 0.0001),	 DMFS	 (P<	
0.0001)	and	BCSS	(P<	0.0001)	(Supplementary	Fig.	2A-2C).	Furthermore,	results	from	the	bc-GenEx-
Miner	v4.0	datasets	showed	that	cases	with	low	expression	of	CDC20	mRNA	had	favourable	clinical	
outcomes	compared	to	the	high	expression	group,	which	showed	poor	clinical	outcome	(P<	0.0001;	
Supplementary	Fig.	2D).	
CDC20	is	a	predic4ve	biomarker	of	poor	response	to	endocrine	therapy	
In	pa\ents	who	received	endocrine	therapy,	tumours	with	high	CDC20	mRNA	expression	were	signi-
ficantly	associated	with	adverse	clinical	outcome,	of	which	high	risk	of	recurrence	(P=0.004;	Fig.	4A)	
and	distant	metastasis	(P=	0.001;	Fig.	4B)	compared	to	pa\ents	with	low	CDC20	expression.	In	term	
of	BCSS,	high	CDC20	mRNA	expression	was	associated	with	worse	survival	and	higher	risk	of	death	
from	breast	cancer	 in	pa\ents	who	were	treated	with	endocrine	therapy	(P<	0.0001,	Fig.	4C)	com-
pared	 with	 CDC20	 low	 expression.	 These	 observa\ons	 were	 validated	 in	 the	 KM-Plocer	 dataset	
where	pa\ents	who	received	endocrine	therapy	with	high	CDC20	mRNA	showed	poor	benefit	form	
the	hormone	 treatment:	RFS	 (P<0.0001),	DMFS	 (P<0.0001)	 and	BCSS	 (P=0.01)	 (Supplementary	 Fig.	
3A-3C)	compared	to	the	low	CDC20	group	who	had	prolonged	survival	and	lower	risk	of	relapse	and	
death	from	breast	cancer.	
The	rela4onship	between	CDC20	mRNA	expression	and	risk	of	relapse	aTer	receiving	5-year	adju-
vant	endocrine	therapy	
In	pa\ents	with	five	years	of	 follow	up	aeer	endocrine	treatment,	results	showed	that	high	CDC20	
mRNA	expression	was	associated	with	high	risk	of	recurrence	(P=	0.008,	Fig.	4D)	and	distant	metas-
tasis	(P=	0.001,	Fig.	4E).	The	significance	of	high	CDC20	mRNA	expression	on	predic\ng	high	risk	of	
recurrence	and	distant	metastasis	on	pa\ents	who	were	treated	with	endocrine	therapy	alone	was	
validated	using	KM-Plocer	datasets	(P<	0.0001;	Supplementary	Fig.	3D	and	3E).	
However,	CDC20	protein	expression	showed	no	prognos\c	associa\on	with	clinical	outcome	on	the	
whole	cohort	of	pa\ents	with	ER+	breast	cancer,	or	the	impact	of	endocrine	therapy	on	pa\ent	sur-
vival,	recurrence	or	distant	metastasis	(P>	0.05;	Fig.	5A-5F).	
CDC20	is	an	independent	prognos4c	marker	in	ER+	breast	cancer	
High	 CDC20	mRNA	 expression	was	 independent	 of	 tumour	 size,	 nodal	 stage	 and	 tumour	 grade	 in	
predic\ng	a	higher	risk	of	recurrence	(P=	0.005),	distant	metastasis	(P=	0.005)	and	death	from	breast	
cancer	(P=	0.0005),	Table	3.	In	those	pa\ents	treated	with	endocrine	therapy	only,	CDC20	mRNA	ex-
pression	was	an	independent	prognos\c	marker	of	tumour	size,	grade	and	nodal	stage	in	predic\ng	
the	risk	of	BCSS	(P=	0.02),	Table	4.	
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DISCUSSION	
Breast	cancer	is	a	heterogeneous	disease	with	various	biological	subtypes	[1]	with	the	most	common	
form	being	ER+/luminal	tumours	[2,3].	This	subtype	remains	heterogeneous	in	terms	of	recurrence,	
mortality	rates,	disease	prognosis	and	response	to	treatment	[3]	despite	acempts	to	biologically	split	
them	into	luminal	A	and	luminal	B.	Endocrine	therapy,	especially	tamoxifen,	s\ll	the	main	treatment	
for	pa\ents	with	ER+	breast	 cancer.	Although	sustained	 treatment	with	 tamoxifen	can	successfully	
reduce	postopera\ve	recurrence	and	mortality	rate,	30	to	50%	of	these	pa\ents	will	develop	resist-
ance	and	later	relapse	[25].	Therefore,	there	is	s\ll	a	need	for	a	more	precise	method	for	stra\fying	
pa\ents	based	on	their	prognosis	and	response	to	endocrine	therapy.	
CDC20	has	a	key	 roles	 in	ac\va\ng	 the	APC/C	 to	 ini\ate	anaphase	and	 late	mitosis	exit	 in	 the	cell	
cycle	 [26,8].	 CDC20	has	 also	been	 shown	 to	be	 a	promising	prognos\c	marker	 for	 a	 variety	of	 tu-
mours;	 including	pancrea\c	 [27,14],	 colorectal	 [15],	 lung	 [16]	and	breast	cancer	 [18].	Here,	we	 fo-
cused	on	the	role	of	CDC20	 in	ER+	breast	cancer	and	especially	 in	pa\ents	who	were	treated	with	
only	endocrine	therapy.	Our	findings	revealed	that	CDC20	is	highly	expressed	in	the	more	aggressive	
and	highly	prolifera\ve	ER+	tumours,	and	implicated	in	resistance	to	endocrine	therapy.	Indeed,	our	
findings	showed	a	significant	associa\on	between	high	CDC20	mRNA	expression	and	the	poor	pro-
gnos\c	clinico-pathological	features	within	ER+	breast	cancer.	Despite	our	observa\ons	that	CDC20	
protein	was	not	prognos\c,	 it	 is	 likely	that	CDC20	expression	plays	a	vital	role	 in	ER+	breast	cancer	
progression.	
Prolifera\on	 has	 a	 key	 role	 in	 the	 clinical	 behaviour	 of	 breast	 cancer	 and	 correlates	 strongly	with	
poor	clinical	outcome	and	drug	resistance.	In	addi\on	to	ER	and	PR,	markers	of	prolifera\on	seems	
to	influence	biological	and	clinical	behaviour	of	ER+	breast	cancer	[19].	 In	 light	of	this,	our	findings	
showed	 that	 high	 CDC20	mRNA	 expression	was	 posi\vely	 correlated	with	 prolifera\on-associated	
genes,	 including	MKI67,	 CCNB1,	 CCNA2	 and	CCND1.	 This	 supports	 the	 results	 of	 previous	 studies,	
which	reported	that	knockdown	of	CDC20	decreased	cell	prolifera\on	and	induced	G2/M	cell	cycle	
arrest	 in	 hepatocellular	 carcinoma	 cells	 [28],	 and	 pancrea\c	 tumours	 [27].	 Altogether,	 these	 data	
suggest	that	CDC20	is	implicated	in	the	prolifera\on	of	ER+	breast	cancer	which	leads	to	tumourige-
nesis	and	aggressiveness	phenotype.	
Despite	recent	efforts	to	develop	new	breast	cancer	biomarkers,	only	ER	and	PR	measurements	are	
used	 currently	 both	 for	 clinical	 diagnosis	 to	 classify	 breast	 cancer	 pa\ents	 and	 as	 a	 guide	 to	 en-
docrine	 therapy	 [29].	Mul\gene	 signatures,	 including	Oncotype	DX,	Mammaprint,	Prosigna,	Breast	
Cancer	 Index	and	EndoPredict,	can	be	valuable	as	addi\onal	prognos\c	tools	with	regard	to	recur-
rence	and	the	stra\fica\on	of	risk,	but	so	far	studies	have	not	validated	their	value	in	predic\ng	ben-
efit	from	endocrine	therapy	[30].	Therefore,	the	iden\fica\on	of	predic\ve	biomarkers	for	endocrine	
therapy	efficacy	in	addi\on	to	ER	and	PR	status	is	of	urgent	need	to	stra\fy	pa\ents	with	ER+	breast	
cancer	for	targeted	therapy.	For	this	purpose,	a	key	aim	of	this	study	was	to	assess	the	predic\ve	val-
!8
ue	of	CDC20	mRNA	and	protein	expression	as	a	clinical	marker	of	benefit	from	endocrine	therapy	in	
ER+	breast	cancer.	Our	clinical	data	found	a	significant	unfavourable	effect	of	CDC20	mRNA	expres-
sion	in	pa\ents	treated	with	endocrine	therapy.	These	findings	lead	to	sugges\on	that	assessment	of	
CDC20	mRNA	expression	prior	to	adjuvant	treatment	could	predict	patents	who	are	highly	to	resist	
the	endocrine	therapy	and	eventually	relapse.		
Results	from	recent	clinical	trials	demonstrated	that	10	years	of	endocrine	therapy	showed	improved	
RFS	and	overall	survival	compared	with	5	years	of	endocrine	treatment	[31,32].	 	However,	this	is	at	
the	cost	of	unnecessary	side	effects	that	influence	the	quality	of	life	for	pa\ents	[33].	Therefore,	it	is	
important	to	iden\fy	a	subgroup	of	pa\ents	who	are	at	high	risk	of	relapse	and	who	will	not	benefit	
from	extended	endocrine	therapy.	Our	study	demonstrates	that	for	pa\ents	with	ER+	breast	cancer	
treated	with	 endocrine	 therapy,	 high	 expression	 of	 CDC20	mRNA	 remains	 a	 predic\ve	marker	 for	
high	risk	of	relapse	and	death	from	breast	cancer	at	5	years	follow	up.	We	suggest	that	assessment	of	
CDC20	mRNA	in	clinical	prac\ce	would	be	useful	to	predict	pa\ents	who	would	not	benefit	from	en-
docrine	therapy	and	could	spare	them	these	risks	and	improve	quality	of	life.	
Although	a	previous	study	has	showed	the	prognos\c	value	of	CDC20	protein	expression	in	pa\ents	
with	triple	nega\ve	breast	cancer	 [18]	we	found	no	associa\on	with	either	clinico-pathological	pa-
rameters	or	pa\ent	clinical	outcome	in	ER+	breast	cancer	or	those	who	treated	with	endocrine	ther-
apy	alone.	This	is	might	be	explained	by	using	different	methods	to	evaluate	the	IHC	staining.	
The	 level	of	 agreement	 in	our	 study	between	 results	of	CDC20	mRNA	and	protein	expression	was	
poor.	This	discrepancy	could	be	explained	by	several	possibili\es,	 including	biological	and	technical	
explana\ons.	 Biological	 reasons	 include	differences	 in	 post-transcrip\onal	 regula\on	of	 CDC20	ex-
pression	or	tumour-specific	differences	in	CDC20	mRNA/protein	stability,	while	technical	issues	may	
include	nature	of	an\body	used	in	this	study	[34-36].	Such	discrepancies	between	mRNA	and	protein	
levels	for	different	reasons	has	occurred	in	mul\ple	studies	of	breast	cancer	[37,38].	
In	summary,	our	data	revealed	a	posi\ve	correla\on	of	high	CDC20	expression	at	the	transcriptomic	
level	with	poor	clinical	outcome	in	pa\ents	with	ER+	breast	cancer.	Also,	we	have	provided	evidence	
that	CDC20	mRNA	expression	 in	ER+	breast	 cancer	 is	a	poten\ally	predic\ve	 for	 selec\ng	pa\ents	
who	might	not	experience	benefits	 from	endocrine	 therapy.	Addi\onal	or	alterna\ve	 target	 thera-
pies	could	then	be	given	to	those	who	predicted	to	be	resistance	to	endocrine	therapy,	this	would	be	
a	significant	shie	toward	truly	individualised	medicine.	We	suggested	that	CDC20	mRNA	expression	
could	be	used	in	clinical	either	singularly	or	in	combina\on	with	other	genes	as	mul\gene	signature	
to	guide	the	choice	of	endocrine	treatment.		
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Figure	legends:	
Figure	1:	A)	Western	bloHng	result	for	CDC20	expression	in	BT474	breast	cancer	cell	lysates.	CDC20	
protein	expression	in	invasive	breast	cancer	cores	using	IHC	B)	Nega\ve	and	C)	posi\ve	CDC20	pro-
tein	expression.		
Figure	2:	Associa\on	of	CDC20	mRNA	expression	with	clinico-pathological	parameters	A)	PR,	B)	NPI	
and	C)	 grade	using	METABRIC	dataset.	CDC20	mRNA	correla\on	with	prilfera\on	associated	genes	
including	D)	MKI67,	E)	CCNB1,	F)	CCNA2	and	G)	CCND1	using	bc-GenExMiner	v4.0	dataset.	
Figure	3:	CDC20	mRNA	and	pa\ent	outcome	in	ER+	breast	cancer	using	METABRIC	dataset:	A)	recur-
rence,	B)	distant-metastasis	and	C)	BCSS.	
Figure	 4:	CDC20	mRNA	expression	 as	 a	 predic\ve	biomarker	 for	 poor	 clinical	 outcome	 in	 pa\ents	
with	ER+	breast	cancer	aeer	endocrine	treatment	using	METABRIC	dataset	A)	recurrence,	B)	distant-
metastasis	and	C)	BCSS.	Kaplan–Meier	survival	plots	for	pateints	with	ER+	breast	cancer	aeer	endo-
crine	treatemnt	and	only	5	years	follow-up	D)	recurrence	and	E)	distant-metastasis.	
Figure	5:	CDC20	protein	and	pa\ent	outcome	in	ER+	breast	cancer	using	NoHngham	cohort:	A)	re-
currence,	B)	distant-metastasis	and	C)	BCSS.	CDC20	protein	expression	and	clinical	outcome	 in	pa-
\ents	with	ER+	breast	cancer	who	were	treated	with	endocrine	therapy	only	using	NoHngham	co-
hort	A)	recurrence,	B)	distant-metastasis	and	C)	BCSS.	
Supplementary	figure	1:	Associa\on	of	CDC20	mRNA	expression	with	clinico-pathological	parame-
ters	using	bc-GenExMiner	v4.0	dataset	A)	PR	and	B)	NoHngham	Prognos\c	Index	(NPI).	
Supplementary	figure	2:	CDC20	mRNA	and	pa\ent	outcome	in	ER+	breast	cancer	using	KM-Plocer	
dataset	for	A)	recurrence,	B)	distant-metastasis	and	C)	BCSS	and	Kaplan–Meier	survival	plots	for	D)	
relapse	breast	cancer	using	bc-GenExMiner	v4.0	dataset.	
Supplementary	figure	3:	CDC20	mRNA	expression	as	a	predic\ve	biomarker	 for	poor	benefit	 from	
endocrine	 therapy	 in	 pa\ents	with	 ER+ breast	 cancer	 aeer	 endocrine	 treatment	 using	 KM-Plocer	
dataset	A)	 recurrence,	B)	 distant-metastasis	 and	C)	 BCSS.	 Kaplan–Meier	 survival	 plots	 for	 pa\ents	
with	ER+	breast	cancer	aeer	endocrine	treatment	and	only	5	years	 follow-up	D)	 recurrence	and	E)	
distant-metastasis.	
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Table	 3:	 Mul$variate	 analysis	 of	 associa$ons	 between	 CDC20	 mRNA	 expression	 and	 clinic-pathological	
parameters	in	endocrine-treated	pa$ents.	
	
Parameters Recurrence	free	survival
HR	(95%	CI) P P*
CDC20	
Tumour	size	
Grade	
Stage
2.1	(1.0-4.3)	
1.2	(0.6-2.1)	
0.9	(0.5-1.5)	
1.1	(0.7-1.7)
0.027	
0.5	
0.81	
0.46
0.1	
1.15	
0.83	
1.01
Breast	cancer	specific	survival
HR	(95%	CI) P P*
CDC20	
Tumour	size	
Grade	
Stage
3.7	(1.5-9.2)	
2.1	(0.9-4.4)	
1.1	(0.5-2.1)	
1.3	(0.8-2.2)
0.004	
0.05	
0.69	
0.22
0.02	
0.1	
0.36	
0.86
P*:	Adjusted	p-value
Table	 2:	 Mul%variate	 analysis	 of	 associa%ons	 between	 CDC20	 mRNA	 expression	 and	 clinic-pathological	
parameters	in	ER+	breast	cancer	pa%ents.	
Parameters Recurrence	free	survival
HR	(95%	CI) P P*
CDC20	
Tumour	size	
Grade	
Stage
2.3	(1.4-4.0)	
1.4	(0.928-2.3)	
1.0	(0.7-1.5)	
1.1	(0.7-1.6)
0.001	
0.1	
0.66	
0.46
0.005	
0.25	
0.77	
0.83
Distant	metastasis	free	survival
HR	(95%	CI) P P*
CDC20	
Tumour	size	
Grade	
Stage
2.7	(1.5-4.9)	
2.0	(1.2-3.5)	
1.1	(0.7-1.7)	
1.4	(0.9-2.0)
0.001	
0.006	
0.46	
0.06
0.005	
0.01	
0.1	
0.5
Breast	cancer	specific	survival
HR	(95%	CI) P P*
CDC20	
Tumour	size	
Grade	
Stage
4.1	(1.9-8.5)	
2.1	(1.2-3.8)	
1.4	(0.8-2.3)	
1.4	(0.9-2.1)
0.000
1	
0.01	
0.14	
0.06
0.0005	
0.02	
0.1	
0.18
P*:	Adjusted	p-value
Table	1:	Clinic-pathological	characteris1cs	of	ER+	breast	cancer	cohort.	
Clinic-pathological	characteris5cs METABRIC	cohort	
mRNA
No>ngham	cohort	
Protein
No.	(%) No.	(%)
Tumour	size	(cm)	
<2	cm	
≥2	cm	
Grade	
1	
2	
3	
No>ngham	Prognos5c	Index	
GPG	
MPG	
PPG	
Endocrine	therapy	
No	
Yes	
Other	
Stage	
1	
2	
3	
PR	
Nega1ve	
Posi1ve
475	(31.5)	
1031	(68.5)	
166	(11.5)	
707	(49.1)	
565	(38.4)	
623	(41.3)	
772	(51.2)	
111	(7.5)	
234	(15.5)	
384	(25.5)	
888	(59)	
404	(36.2)	
634	(56.8)	
78	(7)	
486	(23.2)	
1020	(76.8)
806	(55.7)	
640	(44.3)	
388	(24.7)	
661	(42.1)	
522	(33.2)	
598	(41.4)	
668	(46.1)	
180	(12.5)	
884	(55.7)	
558	(35)	
149	(9.3)	
1025	(65.1)	
439	(27.9)	
111	(7)	
300	(21.3)	
1103	(78.7)
GPG:	Good	prognos1c	group;	MPG:	Moderate	prognos1c	group;	PPG:	Poor	prognos1c	group
Table	2:	Correla(on	of	CDC20	mRNA	expression	with	the	expression	of	prolifera(on	genes	in	ER+	
breast	cancer	using	METABRIC	datasets.	
CDC20	mRNA
Correla(on	Coefficient	(p	value) P*
MKI67	
CCNB1	
CCNA2	
CCND1
1.86e-211	
1.63e-162	
1.79e-223	
6.16e-18
P*:	Adjusted	p-value
A
b ca
ed
Endocrine-treated cohort 
5 years follow-up
Endocrine-treated cohort 
5 years follow-up
Endocrine-treated cohort Endocrine-treated cohort Endocrine-treated cohort
a b c
ed f
a
CDC20	55	kDa	
B-actin	44	kDa		
BT474
b c
C
D
C
2
0
 m
R
N
A
a b
a b c
ed
d
cba
A
D
CB
a b c
cba
P< 0.0001
P< 0.0001
P< 0.0001
P< 0.0001
P< 0.0001
P< 0.0001
P< 0.0001
gfed
P< 0.0001P< 0.0001P< 0.0001P< 0.0001
